Valence Labs

About

Valence Labs (previously known as Valence Discovery) is developing novel algorithms for low-data drug discovery, removing access to data as the principal roadblock when deploying machine learning in pharmaceutical R&D. With an initial focus on cancer and rare diseases, the venture aims to generate, screen, and optimize compounds with up to 1000x less training data than possible using conventional deep learning methods. It was acquired by Recursion Pharmaceuticals in May 2023.